GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2008

Wyeth Decides to End Cardiovascular Research Collaboration with Curis

  • Wyeth has decided to axe development efforts on the Hedgehog agonist program with Curis, which is still in the preclinical phase. The partnership will conclude on May 6.

    Under the original agreement, which was entered into in January 2004, Curis licensed its Hedgehog protein and small molecule pathway agonists to Wyeth. The firms focused preclinical R&D on stroke and cardiovascular disease treatments.

    “We remain hopeful about the future prospects of the Hedgehog agonist as a potential therapeutic for various diseases and we will seek a new partner to continue advancing this program,” remarks Daniel R. Passeri, president and CEO of Curis. “Our internal data and third-party publications suggest that Hedgehog agonists may provide therapeutic benefit in several disease areas including neurological, cardiovascular, and bone disorders as well as for wound healing and hair growth.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?